CoChat

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

Open access

Published version of a preprint

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

A novel SARS-CoV-2 variant termed B.1.526 was recently identified in New York City and has been found to be spreading at an alarming rate. The variant has mutations in its spike protein that might allow it to escape neutralization by vaccine-elicited antibodies and might cause monoclonal antibody therapy for COVID-19 to be less successful.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.01386-21

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Analysis of B.1.526 pseudotyped lentiviral virions. (A) The domain structure of the wild-type SARS-CoV-2 spike protein is shown above. NTD, N-terminal domain; RBD, receptor-binding domain; RBM, receptor-binding motif; SD1 subdomain 1; SD2, subdomain 2; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane region; IC, intracellular domain. The locations of the mutations in the two B.1.526 spike proteins are diagrammed below with the distinguishing E484K and S477N mutations in bold. (B) The locations of the B.1.526 variant spike protein mutations are shown on the 3D structure of the trimeric spike protein. One RBD region is shown for simplicity. The 484 (red) and 477 (blue) amino acid residues are indicated. (C) Immunoblot analysis of B.1.526 spike protein pseudotyped lentiviral virions and cell lysates of transfected producer cells. The blots were probed for the full-length S and processed S2 proteins and with anti-P24 antibody to detect the virions. GAPDH served as a loading control for the cell lysates. Arrows indicate the full-length spike (S), S2 subunit (S2). (D) Infectivity of B.1.526 pseudotyped virus in ACE2.293T cells. ACE2.293T cells were infected with pseudotyped viruses normalized for RT activity. Luciferase activity was measured 2 days postinfection as relative light units (RLU).
FIG 1 Analysis of B.1.526 pseudotyped lentiviral virions. (A) The domain structure of the wild-type SARS-CoV-2 spike protein is shown above. NTD, N-terminal domain; RBD, receptor-binding domain; RBM, receptor-binding motif; SD1 subdomain 1; SD2, subdomain 2; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane region; IC, intracellular domain. The locations of the mutations in the two B.1.526 spike proteins are diagrammed below with the distinguishing E484K and S477N mutations in bold. (B) The locations of the B.1.526 variant spike protein mutations are shown on the 3D structure of the trimeric spike protein. One RBD region is shown for simplicity. The 484 (red) and 477 (blue) amino acid residues are indicated. (C) Immunoblot analysis of B.1.526 spike protein pseudotyped lentiviral virions and cell lysates of transfected producer cells. The blots were probed for the full-length S and processed S2 proteins and with anti-P24 antibody to detect the virions. GAPDH served as a loading control for the cell lysates. Arrows indicate the full-length spike (S), S2 subunit (S2). (D) Infectivity of B.1.526 pseudotyped virus in ACE2.293T cells. ACE2.293T cells were infected with pseudotyped viruses normalized for RT activity. Luciferase activity was measured 2 days postinfection as relative light units (RLU).CC BY · PubMed Central
FIG 2 Convalescent serum, antibodies elicited by BNT162b2 vaccine, antibodies elicited by mRNA-1273 vaccine, antibody REGN10933, and antibody REGN10987 all neutralize B.1.526 variant spikes. (A) Neutralization of viruses with D614G, B.1.526 variant spikes by convalescent-phase sera (n = 6). The data are shown as the percentage infectivity in the absence of serum (left). IC50 (serum dilution) of sera from convalescent individuals (n = 6) against virus with B.1.526 and E484K variant spikes (right). (B) Neutralizing titers of serum samples from BNT162b2-vaccinated individuals (n = 5) (left) and mRNA-1273-vaccinated donors (n = 3) (right) were measured. IC50 values of neutralization of virus with D614G, B.1.1.7, B.1.351, and B.1.526 are shown. (C) A 1:1 mixture of the two antibodies was measured on viruses pseudotyped with B.1.526, D614G and E484K variant spike proteins. Neutralization curves of REGN10933, REGN10987, and a 1:1 mixture of REGN10933 and REGN10987 on viruses with the B.1.526, D614G and E484K variant spike proteins. (D). The effect of the MAb ratio on neutralization of variant B.1.526 (E484K) was tested by holding REGN10933 constant at its IC50 and titrating in REGN10987 (left) or holding REGN10987 constant at its IC50 and titrating in REGN10933.
FIG 2 Convalescent serum, antibodies elicited by BNT162b2 vaccine, antibodies elicited by mRNA-1273 vaccine, antibody REGN10933, and antibody REGN10987 all neutralize B.1.526 variant spikes. (A) Neutralization of viruses with D614G, B.1.526 variant spikes by convalescent-phase sera (n = 6). The data are shown as the percentage infectivity in the absence of serum (left). IC50 (serum dilution) of sera from convalescent individuals (n = 6) against virus with B.1.526 and E484K variant spikes (right). (B) Neutralizing titers of serum samples from BNT162b2-vaccinated individuals (n = 5) (left) and mRNA-1273-vaccinated donors (n = 3) (right) were measured. IC50 values of neutralization of virus with D614G, B.1.1.7, B.1.351, and B.1.526 are shown. (C) A 1:1 mixture of the two antibodies was measured on viruses pseudotyped with B.1.526, D614G and E484K variant spike proteins. Neutralization curves of REGN10933, REGN10987, and a 1:1 mixture of REGN10933 and REGN10987 on viruses with the B.1.526, D614G and E484K variant spike proteins. (D). The effect of the MAb ratio on neutralization of variant B.1.526 (E484K) was tested by holding REGN10933 constant at its IC50 and titrating in REGN10987 (left) or holding REGN10987 constant at its IC50 and titrating in REGN10933.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 75

Metadata

Authors
Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T.
Affiliations
  • New York University (US)
  • NYU Langone Health (US)
Corresponding author
Landau, Nathaniel R.
Venue
mBio
Published
2021-08-31
Volume
12
Issue
4
Pages
e0138621-e0138621
ISSN
2150-7511 (ISSN-L)
OpenAlex
W3184808136
Cited by
68
References
36
Citations by year
2025: 4 · 2024: 3 · 2023: 3 · 2022: 16 · 2021: 42
FWCI
5.06
Type
journal article
Language
en
Open access
Licence
Locations
  • mBio (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
HHS | NIH | OSC | Common Fund (DA046100, AI122390, AI120898, UM1AI148574)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
SARS-CoV-2, E484K mutation, spike protein mutations, antibody neutralization, vaccine-elicited antibodies, therapeutic monoclonal antibodies, COVID-19 vaccine effectiveness, New York City

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. https://app.cochat.ai/papers/10.1128/mbio.01386-21
The paper
Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021). B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. mBio. https://doi.org/10.1128/mbio.01386-21

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.